Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Purdue Pharma L.P. et al v. Amneal Pharmaceuticals, LLC
Case Number:
1:13-cv-03372
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
April 08, 2016
Fed. Circ. Won't Revive OxyContin Anti-Abuse Patent
The Federal Circuit on Friday upheld a district court's finding that a Purdue Pharma patent for an abuse-resistant variety of OxyContin is invalid as obvious, sealing a win for generic-drug maker Amneal Pharmaceuticals.
-
April 08, 2015
Purdue's Anti-Abuse OxyContin Patent Claims Found Invalid
A New York federal judge on Wednesday ruled that although Amneal Pharmaceuticals LLC infringed Purdue Pharma LP's patent with its generic version of an abuse-resistant variety of the pain medication OxyContin, Purdue's asserted claims are invalid as obvious and indefinite.
-
May 28, 2014
Judge Sends Abuse-Resistant OxyContin Patents To Trial
A New York federal judge on Tuesday issued a major claims construction ruling for two of Purdue Pharma LP's OxyContin patents that are designed to prevent abuse of the painkiller, clearing the way for a July bench trial with generic producers over whether the patents are valid.